Guidance On The Use Of Esketamine Nasal Spray For Treatment Resistant Depression

White, Jacquie; Feetam, Celia

Abstract

This guidance was commissioned by Janssen-Cilag Ltd as part of an extensive programme of work to support practitioners across the UK to apply best practice to the supervised self-administration of esketamine nasal spray. The document was generated without input from Janssen-Cilag Ltd and the company had no editorial control over the content. Approval prior to publication on the Janssen Medical Cloud was granted following medical (peer) review by Janssen's parent company Johnson and Johnson.

Citation

White, J., & Feetam, C. (2021). Guidance On The Use Of Esketamine Nasal Spray For Treatment Resistant Depression. Janssen Medical Cloud for UK Healthcare Professionals

• Other Type: Manual / Guide
• Acceptance Date: Apr 1, 2021
• Online Publication Date: Apr 1, 2021
• Publication Date: 2021
• Deposit Date: May 20, 2021
• Publicly Available Date: Oct 27, 2022
• Pages: 95
• Keywords: Clinical guideline, medicines management, pharmacology, intranasal administration, major depressive disorder
• Public URL: https://hull-repository.worktribe.com/output/3772297
• Additional Information: This is a knowledge exchange output for a novel antidepressant that is administered via the intranasal route (antidepressants are traditionally administered by the oral route) . Intranasal administration is a route of administration where a medicine is insufflated through the nose. Whilst this route of medicine delivery is not uncommon in other therapeutic areas, esketamine nasal spray is the first medicine to be available for intranasal administration for the treatment of a mental illness. Co-authored with a Specialist Mental Health Pharmacist the document is intended to provide guidance for prescribers and other healthcare professionals (HCPs) on the correct use of this novel treatment in practice.